Alnylam Pharmaceuticals, Inc.
Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases with unmet need. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran) and GIVLAARI® (givosiran). In addition, Alnylam has six investigational medicines in late-stage development. For more information please visit www.alnylam.com.